European Journal of Clinical Pharmacology

, Volume 36, Issue 6, pp 625–627 | Cite as

Sustained-release and instant-release verapamil in treatment of angina pectoris

  • C. M. Jespersen
  • N. A. Klitgaard
  • H. Nielsen
  • J. Fischer Hansen
Short Communications

Summary

The efficacy of a sustained-release preparation of verapamil (verapamil-IR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations.

The diurnal serum concentrations of verapamil and norverapamil did not differ significantly during treatment with verapamil-IR 120 mg t.i.d. and verapamil-SR 360 mg once daily, but verapamil-SR 240 mg produced significantly lower serum concentrations. The differences did not affect the exercise capacity or the occurrence of ST-segment depression during maximal exercise.

Verapamil-SR was well tolerated. A multiple instant-release dosage regime can now be replaced by once daily administration of the sustained-release preparation.

Key words

verapamil angina pectoris sustained-release formulations serum levels 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anderson P (1986) Pharmacokinetics of calcium channel blocking agents. Acta Pharmacol Toxicol 58 [Suppl 2]: 43–57Google Scholar
  2. 2.
    Lim CK, Rideout JM, Sheldon JWS (1983) Determination of verapamil and norverapamil in serum by high-performance liquid chromatography. J Liquid Chromatogr 6: 877–893Google Scholar
  3. 3.
    Kohli RS, Rodrigues EA, Hughes LO, Lahiri A, Raftery EB (1987) Sustained-release verapamil, a once-daily preparation: Objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina. J Am Coll Cardiol 9: 615–621Google Scholar
  4. 4.
    Rodrigues EA, DasGupta P, Hains ADB, Raftery EB (1988) An objective evaluation of once-daily sustained-release verapamil (480 mg) in chronic stable angina. Eur J Clin Pharmacol 34: 531–532Google Scholar
  5. 5.
    Midtbø K, Hals O, Van der Meer J, Storstein L, Lauve O (1986) Instant and sustained-release verapamil in treatment of essential hypertension. Am J Cardiol 57D–59DGoogle Scholar
  6. 6.
    Mølgaard H, Bjerregaard P, Jørgensen HS, Klitgaard NA (1987) A comparison of the 24-hour antiarrhythmic effect of verapamil, given in conventional and a new slow-release formulation in patients with chronic atrial fibrillation. Eur J Clin Pharmacol 33: 447–453Google Scholar
  7. 7.
    Follath F, Schutz E, Bühler F (1986) Pharmacokinetics of conventional and slow-release verapamil. Br J Clin Pharmacol 21: 149S-153SGoogle Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • C. M. Jespersen
    • 1
  • N. A. Klitgaard
    • 2
  • H. Nielsen
    • 1
  • J. Fischer Hansen
    • 1
  1. 1.Medical Department, Division of CardiologyKøbenhavns KommunehospitalCopenhagenDenmark
  2. 2.Department of Clinical ChemistryOdense University HospitalOdenseDenmark

Personalised recommendations